RTP Mobile Logo
Breast Cancer Update, Issue 1, 2011
Released April 2011

Featuring interviews with Dr Sandra M Swain, Profs Alan Ashworth and Michael Untch and Drs Luca Gianni and Nicholas J Robert. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Breast cancer is one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing clinical trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic, prognostic and even predictive tools. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES
    • Determine the utility of genomic assays for counseling patients with ER-positive early breast cancer about their risk of recurrence and the potential benefits of adjuvant chemotherapy.
    • Develop evidence-based treatment approaches for patients with HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings.
    • Evaluate the unique mechanisms of action and emerging clinical data for novel anti-HER2 agents under investigation in breast cancer.
    • Appraise the risks and benefits of bevacizumab-based therapy for patients with HER2-negative metastatic breast cancer.
    • Summarize the presumed mechanism of action of PARP inhibitors in breast cancer, particularly in patients with BRCA1/2 mutations and/or triple-negative disease.
    • Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY


    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.
     
    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYProf Untch had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SwainPaid Research: Bristol-Myers Squibb Company, Genentech BioOncology; Paid Travel: Sanofi-Aventis. Prof AshworthConsulting Agreements: GlaxoSmithKline, Pfizer Inc; Patent: AstraZeneca Pharmaceuticals LP. Dr GianniAdvisory Committee: Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi-Aventis; Consulting Agreements: Biogen Idec, GlaxoSmithKline, Millennium — The Takeda Oncology Company. Dr RobertAdvisory Committee and Paid Research: Sanofi-Aventis; Consulting Agreement: Novartis Pharmaceuticals Corporation; Speakers Bureau: Roche Laboratories Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, Genomic Health Inc and Sanofi-Aventis.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2011
    Expiration date: April 2012

Acknowledge and close

Listen to audio:
Breast Cancer Update, Issue 1, 2011
Released April 2011

Featuring interviews with Dr Sandra M Swain, Profs Alan Ashworth and Michael Untch and Drs Luca Gianni and Nicholas J Robert. (Text and Audio Content)

Read print: